PNT - POINT Biopharma slips after pipeline update
2023-08-14 10:46:36 ET
More on POINT Biopharma
- POINT Biopharma: Leading The Future Of Radioligand Therapy
- POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials
- POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financials
- Lantheus, POINT Biopharma receive FDA Fast Track status for prostate cancer candidate
- Point Biopharma slumps 35% on license deal with Lantheus for cancer drugs
For further details see:
POINT Biopharma slips after pipeline update